S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.10
+62.50
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TNYA · Tenaya Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Tenaya Therapeutics Inc (TNYA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.39
-0.02
(-5.73%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.39
$0.39
$0.42
52-WEEK RANGE
$0.39
$0.36
$2.02
What's happening
- TNYA is down 5.73% today, trading at $0.39. — Live quote
- It's trading within 3% of its 52-week low ($0.36). (Finnhub fundamentals)
- Volume today (28,488) is well below its 3-month average of 2,653,450. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.20 actual vs. $-0.07 estimated (-186.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TNYA
-42.42%
vs S&P 500
-55.19%
1-YEAR RETURN
TNYA
-79.19%
vs S&P 500
-93.75%
6-MONTH RETURN
TNYA
-45.12%
3-MONTH RETURN
TNYA
-50.28%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.20
Est. $-0.07
MISS -186.9%
2026-04-26 (Q1 2026)
$-0.09
Est. $-0.09
MISS -1.2%
2026-01-26 (Q4 2025)
$-0.12
Est. $-0.12
BEAT +3.0%
2025-10-26 (Q3 2025)
$-0.12
Est. $-0.15
BEAT +20.4%
Valuation Measures & Ratios
Enterprise Value4$13.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.31
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-108.05%
Return on Assets (ROA9)-85.84%
Avg Volume (3M)2,653,450
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $158.3M | $148.9M | $275.4M | $101.5M | $63.8M |
| P/E | -1.49 | -1.66 | -2.87 | -0.96 | -0.56 |
| Price/Book | 2.28 | 1.40 | 3.32 | 1.02 | 0.53 |
| EV/EBITDA | -0.79 | -0.81 | -2.42 | — | — |
| ROE | -153.04% | -84.47% | -115.91% | -105.39% | -95.61% |
| ROA | -113.56% | -66.41% | -91.50% | -86.13% | -79.30% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short22,922,426
Change from Prior Settlement+5.92%
% of Float—
Days to Cover (Short Ratio)7.55
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -79.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TNYA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $225.0K | — | $0 | $0 | — | — | — |
| Operating income | -$44.1M | -$20.1M | -$20.9M | -$24.1M | -$27.5M | -$26.7M | -$30.8M | -$33.8M |
| Net income | -$43.4M | -$19.3M | -$20.3M | -$23.3M | -$26.9M | -$25.6M | -$29.4M | -$32.2M |
| EPS (diluted) | $-0.20 | $-0.09 | $-0.12 | $-0.14 | $-0.24 | $-0.30 | $-0.34 | $-0.40 |
| EPS (basic) | $-0.20 | $-0.09 | $-0.12 | $-0.14 | $-0.24 | $-0.30 | $-0.34 | $-0.40 |
| Operating margin | -$4.0K | -$8.9K | — | — | — | — | — | — |
| Net margin | -$3.9K | -$8.6K | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $93.5M | $135.1M | $146.9M | $105.0M | $122.2M | $144.0M | $119.9M | $140.6M |
| Total liabilities | $24.1M | $28.9M | $23.7M | $22.1M | $22.3M | $24.6M | $27.1M | $28.0M |
| Stockholders' equity | $69.4M | $106.2M | $123.3M | $82.9M | $99.8M | $119.4M | $92.9M | $112.6M |
| Total current assets | $86.0M | $96.6M | $105.6M | $61.2M | $75.9M | $94.5M | $67.4M | $85.3M |
| Total current liabilities | $19.0M | $16.8M | $15.4M | $13.2M | $12.7M | $14.2M | $16.0M | $16.2M |
| Cash & equivalents | $78.1M | $80.9M | $100.5M | $56.3M | $62.7M | $53.8M | $4.3M | $8.2M |
| Marketable securities (current) | — | — | — | — | $9.0M | $34.4M | $57.1M | $71.2M |
| Accounts receivable | $371.0K | $10.6M | — | — | — | — | — | — |
| Other current assets | $4.1M | $25.0K | $1.0M | $990.0K | $218.0K | $1.2M | $842.0K | $1.4M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.5M | $26.0M | $27.7M | $29.4M | $31.3M | $33.4M | $35.9M | $37.8M |
| Other non-current assets | $2.1M | $3.8M | $4.2M | $4.2M | $4.3M | $4.8M | $4.8M | $4.9M |
| Accounts payable | $2.9M | $1.9M | $3.6M | $2.8M | $3.3M | $5.1M | $5.2M | $5.8M |
| Accrued liabilities | $7.5M | $6.0M | $8.8M | $7.4M | $6.5M | $6.3M | $8.0M | $7.3M |
| Deferred revenue (current) | $5.7M | $5.7M | — | — | — | — | — | — |
| Other current liabilities | $324.0K | $455.0K | $176.0K | $186.0K | $142.0K | $350.0K | $214.0K | $435.0K |
| Other non-current liabilities | $103.0K | $418.0K | $410.0K | $301.0K | $293.0K | $287.0K | $281.0K | $276.0K |
| Common stock & paid-in capital | $22.0K | $21.0K | $21.0K | $16.0K | $16.0K | $16.0K | $8.0K | $8.0K |
| Retained earnings | -$667.7M | -$624.3M | -$605.0M | -$584.8M | -$564.6M | -$541.3M | -$514.4M | -$490.6M |
| Accumulated other comprehensive income (loss) | — | — | $0 | — | -$1.0K | -$10.0K | $28.0K | $76.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.6M | -$19.2M | -$13.9M | -$15.6M | -$15.6M | -$23.1M | -$18.4M | -$19.8M |
| Investing cash flow | -$159.0K | -$11.0K | -$67.0K | $8.9M | $25.0M | $22.3M | $14.1M | -$30.1M |
| Financing cash flow | $909.0K | -$415.0K | $58.2M | $380.0K | -$476.0K | $50.3M | $377.0K | $31.0K |
| Free cash flow | -$3.7M | -$19.2M | -$14.0M | -$15.6M | -$15.8M | -$23.5M | -$18.6M | -$20.0M |
| Capital expenditures | $159.0K | $11.0K | $67.0K | $26.0K | $142.0K | $383.0K | $204.0K | $184.0K |
| Depreciation & amortization | $1.7M | $1.8M | $1.8M | $1.9M | $2.1M | $2.7M | $2.1M | $2.1M |
| Share-based compensation | $1.7M | $2.2M | $2.7M | $2.9M | $3.6M | $3.7M | $3.8M | $3.9M |
| Change in accounts receivable | -$10.3M | $10.6M | — | — | $0 | $0 | — | — |
| Change in accounts payable | $988.0K | -$1.5M | $531.0K | -$447.0K | -$1.1M | -$379.0K | -$701.0K | $1.3M |
| Purchases of investments | — | — | $0 | $0 | — | — | $2.0M | $50.6M |
| Sales/maturities of investments | — | — | — | $0 | $0 | $11.0M | — | — |
| Other investing activities | — | — | $0 | $0 | $0 | — | $0 | -$12.0K |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M |
| EPS (diluted) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
| EPS (basic) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M |
| Stockholders' equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M |
| Total current assets | $105.6M | $67.4M | $111.6M | $193.8M | $255.4M |
| Total current liabilities | $15.4M | $16.0M | $22.7M | $24.2M | $21.8M |
| Cash & equivalents | $100.5M | $4.3M | $45.7M | $95.3M | $38.1M |
| Marketable securities (current) | — | $57.1M | $59.0M | $91.3M | $213.2M |
| Other current assets | $1.0M | $842.0K | $1.2M | $938.0K | — |
| Marketable securities (non-current) | — | — | — | $17.7M | — |
| Property, plant & equipment | $27.7M | $35.9M | $43.3M | $51.0M | $43.0M |
| Other non-current assets | $4.2M | $4.8M | $5.7M | $4.8M | $4.1M |
| Accounts payable | $3.6M | $5.2M | $5.6M | $9.6M | $10.7M |
| Accrued liabilities | $8.8M | $8.0M | $12.8M | $10.7M | $9.1M |
| Other current liabilities | $176.0K | $214.0K | $478.0K | $545.0K | $162.0K |
| Other non-current liabilities | $410.0K | $281.0K | $253.0K | $228.0K | $182.0K |
| Common stock & paid-in capital | $21.0K | $8.0K | $7.0K | $7.0K | $4.0K |
| Retained earnings | -$605.0M | -$514.4M | -$403.3M | -$279.2M | -$155.5M |
| Accumulated other comprehensive income (loss) | $0 | $28.0K | -$106.0K | -$378.0K | -$141.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M |
| Investing cash flow | $56.1M | $1.1M | $48.7M | $83.7M | -$238.6M |
| Financing cash flow | $108.4M | $47.7M | $4.0M | $77.8M | $209.0M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M | -$85.9M |
| Capital expenditures | $618.0K | $1.0M | $1.2M | $20.6M | $25.1M |
| Depreciation & amortization | $8.4M | $8.5M | $8.7M | $6.5M | $3.0M |
| Share-based compensation | $13.0M | $16.5M | $15.3M | $11.5M | $3.0M |
| Change in accounts payable | -$1.4M | -$581.0K | -$3.3M | $1.7M | $8.6M |
| Purchases of investments | $0 | $87.1M | $56.6M | $140.5M | $213.4M |
| Other investing activities | $0 | -$17.0K | $25.0K | -$8.0K | — |
| Share repurchases | — | — | — | — | $13.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TNYA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-17 to 2026-09-10
Recent transactions
- Insiders have net sold 37,652 shares over the last 182 days, across 0 purchases and 11 sales.
- Most recent: Ali Faraz (Chief Executive Officer) — Grant / award of 122,000 shares on 2026-09-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)37,652 sh(11 txns)
Net Shares-37,652
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Ali Faraz | Chief Executive Officer | Grant / award | 2026-09-10 | 122,000 |
| Tingley Whittemore | Chief Medical Officer | Grant / award | 2026-09-10 | 49,000 |
| Higa Tomohiro | SVP, Finance | Open market sale | 2026-05-18 | 1,485 |
| COLUMN GROUP III GP, LP | Reporting person | Open market sale | 2026-02-25 | 1,649,281 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | Ali Faraz | Chief Executive Officer | Grant / award | 122,000 | $0.00 |
| 2026-09-10 | Tingley Whittemore | Chief Medical Officer | Grant / award | 49,000 | $0.00 |
| 2026-08-17 | Ali Faraz | Chief Executive Officer | Open market sale | 5,837 | $0.71 |
| 2026-08-17 | Ali Faraz | Chief Executive Officer | Open market sale | 3,969 | $0.71 |
| 2026-08-17 | Ali Faraz | Chief Executive Officer | Open market sale | 5,020 | $0.71 |
| 2026-08-17 | Ali Faraz | Chief Executive Officer | Open market sale | 7,406 | $0.71 |
| 2026-08-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,637 | $0.71 |
| 2026-08-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,637 | $0.71 |
| 2026-08-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,871 | $0.71 |
| 2026-08-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 2,279 | $0.71 |
| 2026-05-18 | Ali Faraz | Chief Executive Officer | Open market sale | 3,390 | $0.79 |
| 2026-05-18 | Tingley Whittemore | Chief Medical Officer | Open market sale | 3,121 | $0.79 |
| 2026-05-18 | Higa Tomohiro | SVP, Finance | Open market sale | 1,485 | $0.79 |
| 2026-02-25 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 1,649,281 | $0.56 |
| 2026-02-25 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 1,862,545 | $0.56 |
| 2026-02-24 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 309,228 | $0.62 |
| 2026-02-24 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 349,212 | $0.62 |
| 2026-02-23 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 143,709 | $0.60 |
| 2026-02-23 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 162,291 | $0.60 |
| 2026-02-20 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 245,965 | $0.61 |
| 2026-02-20 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 277,769 | $0.61 |
| 2026-02-17 | Higa Tomohiro | SVP, Finance | Open market sale | 611 | $0.64 |
| 2026-02-17 | Higa Tomohiro | SVP, Finance | Open market sale | 836 | $0.64 |
| 2026-02-17 | Higa Tomohiro | SVP, Finance | Open market sale | 2,022 | $0.64 |
| 2026-02-17 | Ali Faraz | Chief Executive Officer | Open market sale | 5,851 | $0.64 |
| 2026-02-17 | Ali Faraz | Chief Executive Officer | Open market sale | 3,979 | $0.64 |
| 2026-02-17 | Ali Faraz | Chief Executive Officer | Open market sale | 5,032 | $0.64 |
| 2026-02-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,642 | $0.64 |
| 2026-02-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,642 | $0.64 |
| 2026-02-17 | Tingley Whittemore | Chief Medical Officer | Open market sale | 1,876 | $0.64 |
| 2026-02-11 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 1,905,115 | $0.68 |
| 2026-02-11 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 2,151,458 | $0.68 |
| 2026-02-10 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 161,422 | $0.82 |
| 2026-02-10 | COLUMN GROUP III GP, LP | Reporting person | Open market sale | 182,295 | $0.82 |
| 2026-02-03 | Higa Tomohiro | SVP, Finance | Grant / award | 29,250 | $0.00 |
| 2026-02-03 | Tingley Whittemore | Chief Medical Officer | Grant / award | 48,750 | $0.00 |
| 2026-02-03 | Ali Faraz | Chief Executive Officer | Grant / award | 158,600 | $0.00 |
| 2025-11-17 | Higa Tomohiro | SVP, Finance | Open market sale | 1,367 | $1.33 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-13 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-28 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-28 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-28 | View on SEC.gov → |
Recent news
Headlines about TNYA (Tenaya Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
TNYA Nov 2026 1.000 put (TNYA261120P00001000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
TNYA Nov 2026 1.000 put (TNYA261120P00001000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
TNYA Jan 2027 0.500 call (TNYA270115C00000500) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA)
ChartMill · 2026-10-17 -
Tenaya Therapeutics Inc. Stock Grades | TNYA
Barron's · 2026-10-16 -
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 2026-10-14 -
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Seeking Alpha · 2026-09-17 -
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Yahoo Finance · 2026-09-14
No headlines in this category right now — try “All”.